PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b clinical trials for type 2 diabetes. The company was incorporated in 2014 and is based in Malmö, Sweden.
Stock data | 2024 | Change |
---|---|---|
Price | $0.5544399275113875 | N/A |
Market Cap | $13.19M | N/A |
Shares Outstanding | 23.79M | N/A |
Employees | 2.00 | N/A |